Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease save search
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Published: 2024-02-13 (Crawled : 08:00) - globenewswire.com
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -5.3%
H: 3.85%
C: 0.54%
first disease cell treatment
BD to Present Next Installment of BD Innovates Series: Spotlight on Peripheral Vascular Disease
Published: 2024-02-12 (Crawled : 22:00) - prnewswire.com
BDX | $233.83 -0.23% 3.49% 780K
|
Health Technology
|
| O: 0.04%
H: 0.72%
C: -1.81%
disease
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
Published: 2024-02-12 (Crawled : 19:00) - biospace.com/
ANTX | $2.42 2.11% 2.07% 45K
|
|
| O: -73.3%
H: 14.23%
C: -4.49%
lung disease trial
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: 8.46%
H: 35.96%
C: 29.21%
st-920 fda disease approval prime ema therapeutics potential
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
Published: 2024-02-12 (Crawled : 13:00) - globenewswire.com
FDMT M | $24.255 -2.24% -2.29% 290K
|
Health Technology
|
| O: 0.24%
H: 2.16%
C: -2.96%
disease trials
Johnson &Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Published: 2024-02-09 (Crawled : 14:30) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
fda disease granted treatment risk designation therapy
Johnson & Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Published: 2024-02-09 (Crawled : 13:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
fda disease granted treatment risk designation therapy
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
Published: 2024-02-08 (Crawled : 21:00) - biospace.com/
BIOR | $0.6199 -2.99% -3.08% 180K
|
Health Care and Social Assistan...
|
| O: -2.03%
H: 2.62%
C: -0.58%
disease symposium therapeutics
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
Published: 2024-02-08 (Crawled : 12:30) - prnewswire.com
SNGX | $0.385 -3.75% -3.9% 490K
|
Health Technology
|
| O: -2.59%
H: 8.68%
C: 8.34%
disease medical
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
Published: 2024-02-08 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.48%
H: 0.16%
C: 0.0%
ALEC | $5.27 -1.31% -1.33% 380K
|
Health Technology
|
| O: 0.0%
H: 2.34%
C: -2.34%
al101 first disease alzheimer’s trial
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
Published: 2024-02-07 (Crawled : 14:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: -0.68%
H: 8.6%
C: 8.09%
disease alzheimer's
Europe Emerging Infectious Disease Diagnostics Market Research Report 2024
Published: 2024-02-06 (Crawled : 23:00) - prnewswire.com
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: -1.25%
H: 0.07%
C: -1.63%
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: -1.25%
H: 0.07%
C: -1.63%
europe disease report research diagnostics market
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 15:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease update parkinson’s
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
NUWE | $0.2501 -15.62% -18.51% 2M
|
Manufacturing
|
| O: 6.25%
H: 0.78%
C: -12.75%
aquadex liver disease series potential therapy
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease parkinson’s
Global OTC/DTC Infectious Disease Diagnostics Analysis, Executive Guides, and Opportunities 2023-2024 and 2027: Privacy and Anonymity, The Internet Effect, & The Wellness Movement Fueling Growth
Published: 2024-02-05 (Crawled : 23:00) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: 0.16%
H: 1.45%
C: 1.41%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
OSUR | News | $5.49 -0.72% -0.73% 760K
|
Health Technology
|
| O: -0.41%
H: 3.14%
C: 2.73%
internet disease global wellness diagnostics growth
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-02-05 (Crawled : 12:30) - globenewswire.com
BRTX | $1.26 -5.97% -6.35% 75K
|
Professional, Scientific, and T...
|
| O: 14.64%
H: 14.33%
C: 7.48%
brtx-100 disease study
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
PTN | $1.73 -1.14% 0.0% 59K
|
Health Technology
|
| O: 0.53%
H: 15.53%
C: 7.11%
pl9643 disease eye trial
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
Published: 2024-02-05 (Crawled : 12:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: 9.48%
H: 15.37%
C: 10.75%
patent disease alzheimer’s application therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.